Evidence map›Paper›PMID 28376643›Full record

ArticleFree radical research2017

Effect of tempol on peripheral neuropathy in diet-induced obese and high-fat fed/low-dose streptozotocin-treated C57Bl6/J mice.

Alexander Obrosov, Hanna Shevalye, Lawrence J Coppey, Mark A Yorek

Abstract read
In one paragraph

Article in Free radical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. [Effect of the chemoprotectant tempol on anti-tumor activity of cisplatin].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019
    Article
  14. Molecules (Basel, Switzerland) · 2019
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alexander Obrosova Department of Internal Medicine , University of Iowa , Iowa City , IA , USA.
Hanna Shevalyea Department of Internal Medicine , University of Iowa , Iowa City , IA , USA.
Lawrence J Coppeya Department of Internal Medicine , University of Iowa , Iowa City , IA , USA.
Mark A Yoreka Department of Internal Medicine , University of Iowa , Iowa City , IA , USA.
University of Iowa · US

Funding

Effect of exogenous fatty acids on diabetes neural/neurovascular complicationsR01DK107399 · NIDDK · UNIVERSITY OF IOWA · PI YOREK, MARK A. · 2016 to 2019
$1.1M
Diabetic Neuropathy: Function-Structure of Corneal Nerves to Assess Injury-RepairI01RX000889 · VA · IOWA CITY VA MEDICAL CENTER · PI KARDON, RANDY H., YOREK, MARK A. · 2015 to 2022
–
NIDDK NIH HHS R01 DK107399RRD VA I01 RX000889
6 · The paper itself

Abstract

In this study, we sought to determine the efficacy of tempol on multiple neuropathic endpoints in a diet-induced obese mouse, a model of pre-diabetes, and a high-fat fed low-dose streptozotocin treated mouse, a model of type 2 diabetes. Tempol (4-hydroxy-2,2,6,6-tetramethylpiperdine -1-oxyl) is a low molecular weight, water soluble, membrane permeable, and metal-independent superoxide dismutase mimetic that has been widely used in cellular studies for the removal of intracellular and extracellular superoxide. This in vivo study was designed to be an early intervention. Fourteen weeks post-high-fat diet (6 weeks post-hyperglycemia) control, obese, and diabetic mice were divided into no treatment and treatment groups. The treated mice received tempol by gavage (150 mg/kg in water), while the untreated mice received vehicle. The diet-induced obese and the diabetic mice were maintained on the high-fat diet for the duration of the study, while the control group was maintained on the standard diet. Obesity and diabetes caused slowing of motor and sensory nerve conduction, reduction in intraepidermal nerve fiber density, thermal hypoalgesia, and mechanical allodynia. Treatment with tempol partially or completely protected obese and diabetic mice from these deficits. These studies suggest that tempol or other effective scavengers of reactive oxygen species may be a viable option for treating neural complications associated with obesity or type 2 diabetes.

Indexed as

AnimalsCyclic N-OxidesDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diet, High-FatDisease Models, AnimalMiceMice, Inbred C57BLObesityPeripheral Nervous System DiseasesSpin LabelsStreptozocinCyclic N-OxidesSpin LabelsStreptozocintempoldiabetesdiabetic neuropathysensory nerve fibersTempol

Identifiers

PMID28376643
PMCPMC5575770
OpenAlexW2604498376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.